top of page

A Bioelectronic Medicine Company

advancing the treatment of autoimmune diseases.


About Us

Boomerang Medical is a women-led bioelectronic medicine company on a mission to disrupt the treatment of autoimmune diseases. The company is developing a bioelectric neuromodulation technology, which has been granted Breakthrough Device Designation by the FDA for the treatment of Crohn's disease and ulcerative colitis. The technology is currently being evaluated in an FDA-approved clinical trial at leading IBD centers in the US. 

Our Focus

Inflammatory Bowel Disease (IBD) is one of the most debilitating autoimmune diseases, affecting millions globally. Living with Crohn's disease or ulcerative colitis impacts not just physical health, but also work, relationships, and well-being. Current treatments include medications and surgery, but the complexity of the condition means that there is always room for innovative approaches.

What if the next big leap in managing IBD is already hardwired into our bodies? That's the question propelling our focus on neuromodulation, a promising frontier in bioelectronic medicine.

Boomerang Medical is dedicated to promoting IBD awareness and education. We are proud to be a member of the Crohn’s & Colitis Foundation's Corporate Circle.

Boomerang Medical is headquartered in the heart of Silicon Valley on the campus of El Camino Hospital in Mountain View, California. We are proud to be a Company–In-Residence at the prestigious Fogarty Innovation incubator–the only healthcare-focused incubator of its kind in the US–giving us access to the brightest minds and expertise in the medical technology industry.


Does Inflammatory Bowel Disease disrupt your daily life?

Researchers in the BOOM-IBD Clinical Trial are exploring whether nerve stimulation, a therapy already approved by the FDA to treat other conditions, can be effective for treating Inflammatory Bowel Disease.

Meet the Team


Board of Directors + Advisors

Boomerang Medical is proud to be a portfolio company of

Arboretum Ventures and Hatteras Venture Partners, as well as a

Company-In-Residence at Fogarty Innovation.


Heather Simonsen

Boomerang Medical

President & CEO


Andrew Cleeland

Fogarty Innovation

Chief Executive Officer

tom shehab_edited.png

Tom Shehab, MD

Arboretum Ventures

Managing Partner

gayle headshot_edited_edited.png

Gayle Kuokka

Fogarty Innovation

Chief Financial Officer

jeff terrell headshot_edited_edited.png

Jeff Terrell

Hatteras Venture Partners

General Partner

Screen Shot 2022-10-10 at 11_edited_edit

John Morriss

Fogarty Innovation

Director of Innovation Acceleration

Scientific Advisors


Peter Irving, MA, MD, FRCP

London Digestive Health

Consultant Gastroenterologist

Kings College London

Professor of Inflammatory Bowel Disease


Edward Barnes, MD, MPH

University of North Carolina at Chapel Hill

Assistant Professor of Medicine,

Associate Fellowship Program Director


Gil Melmed, MD


Director of Inflammatory Bowel Disease Clinical Research Medicine

Kevin Benson, MD


Sanford Health 

Urogynecologist, Obstetrician

Warren Grill, PhD


Duke University 

Edmund T. Pratt, Jr. School Distinguished Professor of Biomedical Engineering

Laura Raffals, MD


Mayo Clinic 

Professor of Medicine, Department of Medicine Associate Chair of Faculty Development, Vice Chair of the Division of Gastroenterology & Hepatology

Corey A. Siegel, MD, MS


Dartmouth-Hitchcock Medical Center 

Section Chief of Gastroenterology and Hepatology, Co-Director of the IBD Center

Christian Stone, MD, MPH


Comprehensive Digestive Institute of Nevada

Gastroenterologist, Inflammatory Bowel Disease Specialist


Savitha Krishnan, MD

El Camino Health

Urogynecologist, Obstetrician

Sophie Payne, PhD


Bionics Institute 

Senior Research Fellow, Head of the Peripheral Interface Neuromodulation Team

Boomerang Medical in the News

Anchor 1

Fogarty Companies Look to Continued Momentum in 2023

Fogarty Innovation | Nov 22, 2022 

At Fogarty Innovation we are fortunate to have a front-row seat as our companies pioneer innovations that solve meaningful problems in patient care.


Here are six women-led life science startups to watch

San Francisco Business Times | Mar 3, 2023

We talked to the CEOs of some of the Bay Area's most promising life science startups to find

The trial will assess the use of nerve stimulation as a potential treatment for Crohn’s disease and ulcerative colitis.


2495 Hospital Drive, Suite 300

Mountain View, CA 94040

(844) 423-9747

bottom of page